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Colon cancer stem cells (colon-CSCs) are more
resistant to conventional chemotherapy than differ-
entiated cancer cells. This subset of therapy refrac-
tory cells is therefore believed to play an important
role in post-therapeutic tumor relapse. In order to
improve the rate of sustained response to conven-
tional chemotherapy, development of approaches
is warranted that specifically sensitize colon-CSCs
to treatment. Here, we report that ER-stress-induced
activation of the unfolded protein response (UPR)
forces colon-CSCs to differentiate, resulting in their
enhanced sensitivity to chemotherapy in vitro and
in vivo. Our data suggest that agents that induce acti-
vation of the UPR may be used to specifically in-
crease sensitivity of colon-CSCs to the effects of
conventional chemotherapy.INTRODUCTION
In many cancers, a small subpopulation of cells is responsible for
tumor initiation, growth, and metastasis (Visvader and Linde-
man, 2012). In the colon, these so-called colon cancer stem cells
(colon-CSCs) are characterized by the expression of cell surface
markers such as CD133 (O’Brien et al., 2007; Ricci-Vitiani et al.,
2007), LGR5 (Barker et al., 2009; Kemper et al., 2012), and
CD166 (Dalerba et al., 2007). Furthermore, these cells display
high levels of ALDH1 enzyme activity (Huang et al., 2009) and
Wnt-signaling activity (Vermeulen et al., 2010). Importantly,
colon-CSCs show increased resistance to conventional chemo-
therapies and are believed to be responsible for tumor regener-
ation after initial response to chemotherapy (Colak andMedema,
2014; Kemper et al., 2010; Rich and Bao, 2007; Valent et al.,
2012; Zeuner et al., 2014). Therefore, therapeutic outcomes after
chemotherapy may be improved with therapies that specifically
target the eradication of colon-CSCs.CMechanisms that regulate stem cell dynamics in the healthy
intestinal epithelium may give fundamental insights into the
biology of their malignant counterparts. An important organelle
that regulates the homeostasis of normal intestinal stem cells is
the ER. Novel proteins that are synthesized in the ER are assis-
ted by chaperones for their proper folding. The major ER
chaperone GRP78 is in a dynamic equilibrium between folding
proteins and ER transmembrane receptors. An increased load
of folding proteins shifts GRP78 away from the transmembrane
receptors, a situation termed ER stress that results in the acti-
vation of the unfolded protein response (UPR). We have
recently shown that activation of the UPR forces normal intes-
tinal epithelial stem cells into differentiation (Heijmans et al.,
2013).RESULTS
Activation of the UPRReduces Stemness of Colon-CSCs
We hypothesized that, if the differentiating effects of the
unfolded protein response (UPR) would be conserved between
normal intestinal stem cells and colon-CSCs, then this may be
exploited to sensitize colon-CSCs to chemotherapy. To specif-
ically investigate the effects of the UPR on colon-CSCs, we
used patient-derived spheroid cultures of colon cancer cells
with Wnt-driven GFP expression (Vermeulen et al., 2010). In
these cultures, colon-CSCs aremarked by highWnt pathway ac-
tivity (Wnthigh), whereas more-differentiated cancer cells have
lower Wnt pathway activity (Wntlow). We have previously estab-
lished that Wnthigh cells exhibit a higher clonogenic potential
and are more resistant to chemotherapy thanWntlow cells (Colak
et al., 2014; Vermeulen et al., 2010), indicating that the Wnt-
driven GFP reporter efficiently distinguishes between CSCs
and more-differentiated cancer cells.
The UPR can be activated in vitro with subtilase cytotoxin AB
(SubAB), a bacterium-derived protease that specifically cleaves
ER chaperone GRP78 (Paton et al., 2006). Gene ontology anal-
ysis of SubAB-treated Wnthigh cells showed that the top
three upregulated gene sets were UPR (p = 1.3 3 1036), ER-
associated catabolic process (p = 3.9 3 1023), and ER lumenell Reports 13, 489–494, October 20, 2015 ª2015 The Authors 489
Figure 1. Activation of the Unfolded Protein
Response in Colon-CSCs Results in Loss of
Stemness
(A) Gene expression analysis of colon-CSCs
(Wnt-GFPhigh) cells treated with SubAB or prote-
ase-dead SubA272B control (24 hr; 1 mg/ml) in
three independent experiments. Treatment with
SubAB resulted in upregulation of UPR target
genes and loss of several intestinal stem cell
markers. These findings were validated on
qRT-PCR (Figure S1A) and were confirmed by
treatment with other UPR-activating agents
thapsigargin and salubrinal (Figures S1B and
S1C) and on other primary spheroid cultures
derived from different patients with colon cancer
(Figure S1D).
(B) Gene set enrichment analysis of SubAB-
treated colon-CSCs revealed profound loss of a
previously described colon-CSC signature (de
Sousa E Melo et al., 2011).
(C) Flow cytometry analysis of 24 hr SubAB
treatment (1 mg/ml) resulted in downregulation
of colon-CSC markers CD133 and LGR5. Data
are representative of three independent experi-
ments.
(D) Experimental setup for (E) and (F). In these
experiments, colon-CSCs (Wnt-GFPhigh) were first
sorted before treatment for 24 hr with SubAB or
SubA272B control (1 mg/ml).
(E) SubAB treatment did not result in increased cell
death in colon-CSCs as assessed by propidium
iodide uptake.
(F) Similar to spheroid culture (C), sorted colon-
CSCs lost expression of LGR5 upon UPR activa-
tion by SubAB.
(G) Limiting dilution assay performed on colon-
CSCs (Wnt-GFPhigh) and differentiated cancer
cells (Wnt-GFPlow). Cells were pre-treated for
24 hr with SubAB or SubA272B control (1 mg/ml)
and plated out in normal CSC medium without
treatment. Exclusion of dead cells was performed
with propidium iodide (PI).
(H) In vivo limiting dilution assay. Colon-CSCs
were pre-treated for 24 hr with SubAB or
SubA272B (1 mg/ml) and sorted in Matrigel with indicated quantities and subcutaneously injected into nude mice. Exclusion of dead cells was performed
with PI.
Values in (E) are mean ± SEM; values in (G) and (H) are mean with 95% CI; *p < 0.05; **p < 0.01; ***p < 0.001.(p = 2.4 3 1022). This confirmed the validity of using SubAB to
induce ER stress and activate the UPR. Interestingly, SubAB
treatment resulted in a significant downregulation of several es-
tablished intestinal-stem-cell-associated genes such as OLFM4
and LGR5 in FACS-sorted colon-CSCs (Wnt-GFPhigh) 24 hr post-
treatment (Figures 1A and S1A). Gene set enrichment analysis
(GSEA) using a previously described colon-CSC gene set
confirmed the loss of expression of genes that define colon-
CSCs (de Sousa E Melo et al., 2011; Figure 1B). This suggests
that ER stress results in loss of the colon-CSC phenotype.
Indeed, a FACS-based analysis showed that treatment with
SubAB reduced expression of CD133 and almost completely
abrogated expression of LGR5 (Figure 1C). Similar to SubAB,
treatment with the UPR-inducing agent thapsigargin also re-
sulted in downregulation of stem cell markers, corroborating
the results obtained with SubAB (Figure S1B). In contrast to490 Cell Reports 13, 489–494, October 20, 2015 ª2015 The Authorsthapsigargin and SubAB, salubrinal inhibits the phosphatase of
eIF2a and thereby only activates the PERK-eIF2a branch of the
UPR (Boyce et al., 2005). Interestingly, salubrinal was equally
effective in downregulating stem cell markers (Figure S1C), sug-
gesting that activation of the PERK-eIF2a branch is sufficient for
UPR-induced differentiation of colon-CSCs, as previously
described for normal intestinal stem cells (Heijmans et al., 2013).
To exclude the possibility that LGR5-positive cells disap-
peared from the spheroid cultures by a process of cell death of
the LGR5-positive colon-CSCs, we now FACS-sorted colon-
CSCs (Wnt-GFPhigh) before start of the treatment (Figure 1D).
Sorted colon-CSCs did not show increased propidium iodide
(PI) uptake upon treatment with SubAB (Figure 1E) and survived
in culture. As previously observed in the unsorted spheroid cul-
tures, LGR5 expression was lost upon treatment (Figure 1F).
Together, these experiments establish that Wnt-GFPhigh cells
Figure 2. Differentiation of Colon-CSCs Oc-
curs toward an Enterocyte Phenotype, and
Loss of Stemness Can Be Reversed
(A) qRT-PCR for differentiation markers relative to
GAPDH at different time points after start of
treatment with SubAB or protease-dead SubA272B
control (1 mg/ml). Data are representative of three
independent experiments.
(B) 3D Matrigel culture showed phenotypic
differentiation by SubAB treatment as seen by
enhanced polarization, smoothening of the outer
layer, and development of a central lumen. Data
are representative of three independent experi-
ments.
(C) Experimental setup for (C) and (D). Spheroid
cultures were harvested for further analysis
directly after 24 hr treatment with SubAB or pro-
tease-dead SubA272B control (1 mg/ml) or 24–48 hr
after replacement of the treatment with normal
CSC medium. qRT-PCR for stem cell markers
LGR5 and OLFM4 relative to GAPDH reveals that
loss of expression of stem cell markers can be
reversed after therapy withdrawal.
(D) Limiting dilution analysis at indicated times
after treatment withdrawal demonstrating that the
loss of self-renewal capacity by UPR activation is
completely lost 48 hr after treatment withdrawal.
Transient salubrinal treatment resulted in similar
reversible effects of UPR-induced differentiation
(Figure S2).
Values in (A)–(C) are mean ± SEM; values in (D)
are mean with 95% CI; *p < 0.05; **p < 0.01;
***p < 0.001.not only lose the transcriptional profile of colon-CSCs but also
lose protein expression of the stem cell marker LGR5 when
exposed to ER stress.
Self-renewal capacity is a hallmark of stemness and can be
determined by limiting dilution analysis. To test the functional
consequences of the ER-stress-induced loss of the colon-CSC
profile and LGR5 protein expression, we performed a limiting
dilution assay. Intriguingly, SubAB treatment resulted in a loss
of self-renewal capacity in vitro and a decrease in potential to
form xenografts in vivo (Figures 1G and 1H), demonstrating
that activation of UPR differentiates colon-CSCs both phenotyp-
ically as well as functionally.
UPR Activation Results in Differentiation of Colon-CSCs
toward an Enterocyte Phenotype
In line with the hypothesis that ER stress may induce dif-
ferentiation of colon-CSCs, loss of expression of stem cell
markers concurred with increased expression of the master in-
hibitor of intestinal stem cell-cycle progression P21Cip1/Waf1 or
cyclin-dependent kinase inhibitor 1 (CDKN1) (van de Wetering
et al., 2002) at 24 hr post-treatment. This was followed by
upregulation of enterocyte markers CK20, VIL2, SI, and FABP2
after 48–72 hr treatment with SubAB (Figure 2A). Intriguingly,
MUC2, a marker of secretory goblet cells, was downregulated,
arguing that ER stress may differentiate intestinal epithelialCstem cells toward an absorptive phenotype rather than a secre-
tory phenotype.
When colon-CSCs were grown in 3D Matrigel culture, SubAB
treatment dramatically increased the percentage of differenti-
ated spheres (90% versus 11%; p < 0.001; Figure 2B) with
increased cellular polarization and the formation of a central
lumen. Taken together, these findings indicate that UPR activa-
tion results in phenotypic differentiation of colon-CSCs.
UPR Induced Loss of Stemness Is Reversed by
Treatment Withdrawal
To investigate to what extent UPR-induced differentiation is
irreversible, we transiently treated spheroid cultures for 24 hr
with SubAB and performed further analyses directly after the
treatment or 24–48 hr after replacement of the treatment with
normal CSC medium (Figure 2C). After 48 hr of treatment with-
drawal, the spheroid cultures had almost completely regained
their OLFM4 expression (Figure 2C). In concordance, UPR-
induced loss of self-renewal capacity was completely reversed
at this time point (Figure 2D). The same observation was made
in salubrinal-treated colon-CSCs (Figures S2A–S2C). These
data clearly indicate that the effects of UPR activation are tran-
sient and are reversed when colon-CSCs are given the oppor-
tunity to recover in the absence of ER stress. Surprisingly, the
expression of LGR5 was even increased at 48 hr post-SubABell Reports 13, 489–494, October 20, 2015 ª2015 The Authors 491
Figure 3. UPR-Induced Differentiation Sen-
sitizes Colon-CSCs to Chemotherapy
In Vitro and In Vivo
(A) Percentages of apoptotic cells, measured by
caspase3 activity (CaspGlow) for colon-CSCs
(Wnt-GFPhigh) and differentiated cancer cells (Wnt-
GFPlow) after indicated treatments. Colon-CSCs
were more resistant to oxaliplatin (24 hr; 50 mM) in
comparison to differentiated cancer cells. Pre-
treatment with SubAB (24 hr; 1 mg/ml) or salubrinal
(Figure S3) resulted in enhanced sensitivity to
oxaliplatin-induced apoptosis.
(B) Sensitization of colon-CSCs was confirmed for
other chemotherapeutic agents 5-FU (200 mg/ml),
FOLFOX (1.25 mMoxaliplatin and 50 mM5-FU), and
FOLFIRI (1 mM irinotecan and 50 mM 5-FU).
(C) Illustration of experimental setup for in vivo
experiments.
(D) Survival curves for xenotransplanted mice,
treated weekly with salubrinal (1mg/kg), oxaliplatin
(1 mg/kg), or a combination of both for 4 weeks.
Values in (A) and (B) are mean ± SEM. Significance
was measured by two-way ANOVA (A), one-way
ANOVA (B), or log rank (Mantel-Cox) test (D), fol-
lowed by Bonferroni post test for multiple com-
parisons. Significance was defined as *p < 0.05,
**p < 0.01, and ***p < 0.001.and salubrinal treatment (Figures 2C and S2C), suggesting that
transient UPR activation may ultimately elicit a regenerative
response in these cells, resulting in expansion of the stem
cell pool.
UPR-Induced Differentiation Sensitizes Colon-CSCs to
Chemotherapy
Colon-CSCs are suggested to be more resistant to con-
ventional chemotherapy and thereby to drive recurrence of
the tumor after initial response to therapy. Indeed, we found
colon-CSCs to be more resistant to oxaliplatin than differenti-
ated cancer cells (Figures 3A and S3), confirming previous
reports (Colak et al., 2014). The specific eradication of these
therapy refractory cells may therefore provide a window of
opportunity to improve outcomes of chemotherapy. We hy-
pothesized that ER-stress-induced colon-CSC differentiation
could be an attractive option to achieve this goal. To test this
hypothesis, spheroid cultures of colon-CSC were treated with
SubAB or salubrinal, followed by conventional chemothera-
peutic regimens. UPR activation sensitized colon-CSCs toward
oxaliplatin and 5-FU but also for chemotherapy regimens
including FOLFOX and FOLFIRI in vitro (Figures 3A, 3B, and
S3). In vivo UPR activation was obtained by treating mice
with salubrinal, because SubAB causes hemolytic uremic syn-
drome (Wang, 2007). In line with the in vitro observations of a
compensatory response elicited by transient UPR activation,
treatment with salubrinal alone resulted in increased growth
of xenografts derived from colon-CSCs. In combination with
oxaliplatin, however, salubrinal suppressed growth of subcu-
taneous xenografts (Figures 3C and 3D). This indicates that
UPR activation sensitizes colon-CSCs toward chemotherapy
in vitro and in vivo.492 Cell Reports 13, 489–494, October 20, 2015 ª2015 The AuthorsDISCUSSION
Forced differentiation of colon-CSCs is an attractive and feasible
avenue in the development of new strategies to achieve a
more-sustained response to chemotherapy. Previously, bone
morphogenetic protein (BMP) signaling was shown to induce
differentiation of colon-CSCs by the inhibition of Wnt signaling,
which increased their sensitivity to chemotherapy (Lombardo
et al., 2011). However, this effect was only found in colon-
CSCs that did not have simultaneous mutations in SMAD4 and
constitutive activation of PI3K. A more-broad effect appears to
be exerted by inhibition of the Notch pathway, which strongly
suppresses cancer stemness (Prasetyanti et al., 2013), and in
addition, neutralizing antibodies against DLL4 were shown to
decrease tumor-initiating cell frequency and sensitize colon-
CSCs to chemotherapy (Hoey et al., 2009).
Our findings now show that induction of ER stress and subse-
quent activation of the UPR is an effective means to induce dif-
ferentiation of colon-CSCs. UPR activation results from various
stimuli that are known to impair cellular integrity such as protein
misfolding or aggregation, oxidative injury, and viral infection. In
normal physiology, UPR-mediated stem cell differentiation may
therefore act as a mechanism to guarantee integrity of the
stem cell pool by forcing the differentiation of damaged stem
cells. Indeed, we recently showed that activation of the UPR in
healthy intestine by genetic deletion of ER chaperone Grp78 re-
sulted in loss of stem cells by differentiation and quick repopula-
tion of healthy stem cells that were not recombined (Heijmans
et al., 2013). This protective function may be preserved for other
healthy and cancerous tissues as well. Likewise, van Galen et al.
(2014) have shown that the integrity of the hematopoietic stem
cell pool is governed by the UPR by clearance of individual
HSCs after stress in order to prevent propagation of damaged
stem cells.
Our in vitro findings show that ER-stress-induced differentia-
tion of CSCs results in their enhanced sensitivity to chemo-
therapy. Our in vivo experiments established that treatment
with salubrinal enhanced the efficacy of oxaliplatin in inhibiting
tumor growth, but it should be noted that this experiment did
not formally examine whether this was due to CSC differentia-
tion. The compensatory regenerative response we observed in
our in vitro experiments within 48 hr after therapy withdrawal in-
dicates that chemotherapy should be administered in a critical
time window after UPR activation. Together, these data identify
the UPR as a pathway that may be targeted to optimize the
sensitivity of colon-CSCs for chemotherapy and improve
outcome in patients with colon cancer.
EXPERIMENTAL PROCEDURES
Cell Culture
Spheroid cultures were isolated from different patients with colon cancer in
accordance with the rules of the medical ethical committee of the AMC.
Spheroid cultures with a TCF/LEF-driven GFP reporter for Wnt-signaling activ-
ity were previously described (Vermeulen et al., 2010). The 10% highest Wnt-
GFP-expressing cells represent the colon-CSC population, whereas the 10%
lowest Wnt-GFP-expressing cells represent differentiated colon cancer cells.
Colon-CSCs were cultured under ultralow-adherent condition as described
previously (Todaro et al., 2007) in CSCmedium. All treatments were performed
after overnight adherence in 12-well plates (50,000 cells per well). For compo-
sition of CSC medium and reagents, see Supplemental Information.
RNA Extraction, Quantitative RT- PCR, and Microarray
Spheroid cultures were adhered overnight and treated for 24 hr with SubAB or
protease-dead SubA272B (1 mg/ml). Colon-CSCs (Wnt- GFP
high) were sorted
and lysed in 350 ml RLT buffer (RNeasy; QIAGEN). RNA extraction was per-
formed according to manufacturer’s instructions. For cDNA synthesis, 1 mg
of RNA was transcribed using Revertaid (Fermentas). qRT-PCR was per-
formed using SybrGreen (QIAGEN) according to manufacturers’ protocol on
a BioRad iCycler using specific primers for the mRNA of interest (see below).
For microarray, RNA was labeled using cRNA labeling kit for Illumina arrays
(Ambion) and hybridized with Illumina HT12 Arrays. The array data were
analyzed on the R2 bioinformatic platform (http://hgserver1.amc.nl/cgi-bin/
r2/main.cgi). Differentially expressed genes were extracted using ANOVA
test (p < 0.05) and FDR post-analysis correction. GSEAs were performed
with GSEA software from the Broad Institute (http://www.broadinstitute.org/
gsea/index.jsp). The gene sets used were previously described (de Sousa E
Melo et al., 2011). Heatmaps were generated using TreeView software gener-
ated by the Eisen lab (http://www.eisenlab.org/eisen).
qRT-PCR Primers
See the Supplemental Information.
Flow Cytometry and FACS Sorting
Spheroid cultures were adhered overnight and treated for 24 hr with SubAB or
protease-dead SubA272B (1 mg/ml). Flow cytometry was performed on trypsin-
dissociated spheroid cultures with anti-LGR5-biotin antibody (4D11F; 1:100;
BD Biosciences) and AC133/CD133-APC antibody (1:25; Miltenyi Biotec).
Dead cells were excluded with PI (1:1,000).
3D Matrigel Differentiation Assay
For 3DMatrigel cultures, trypsin-dissociated spheroid cultures were dissolved
in ice cold, liquid Matrigel and allowed to solidify at 37C before addition of
CSCmedium. Treatment were added to the 3DMatrigel cultures 2 days there-
after and continued for 4 days. Quantification of differentiated spheres wasCperformed by three independent observers that were blinded for the
treatment.
Limiting Dilution Assays
For in vitro limiting dilutions, spheroid cultures were pre-treated for 24 hr with
SubAB or protease-dead SubA272B control (1 mg/ml). Colon-CSC (Wnt-
GFPhigh) and differentiated colon cancer cells (Wnt-GFPlow) were sorted into
a 96-well plate containing normal CSC medium without treatment at 1, 2, 4,
8, 16, 32, 64, 128, and 256 cells per well. Dead cells were excluded with PI.
In Vitro Cell Death Assays
Spheroid cultures were pre-treated for 24 hr with SubAB or protease-dead
SubA272B (1 mg/ml) followed by 24 hr treatment with chemotherapeutic regi-
mens (see the Supplemental Experimental Procedures); oxaliplatin (50 mM),
5-FU (200 mg/ml), FOLFOX (1.25 mM oxaliplatin followed after 90 min by
50 mM 5-FU), and FOLFIRI (irinotecan 1 mM followed after 90 min by 50 mM
5-FU). To compare colon-CSCs (Wnt-GFPhigh) to differentiated cancer cells
(Wnt-GFPlow), apoptosis was measured at the single-cell level by caspase 3
activity using CaspGlow active staining kit (Red-DEVD-FMK) according to
the manufacturer’s instructions (BioVision). In short, after treatment, spheroid
cultures were made single cells using trypsin-EDTA. Fifty thousand cells were
washed with CSC medium and stained with RED-DEVD-FMK for 1 hr at 37C.
Subsequently, cells were washed twice with wash buffer.
Animal Experiments
The protocol of this study was approved by the animal ethics committee of the
University of Amsterdam (permit number ALC102862). For xenograft studies,
7.000 FACS-sorted Wnt-GFPhigh cells were suspended in 100 ml of PBS/BSA
mixed with Matrigel at a 1:1 ratio and injected subcutaneously into nude
mice (Hsd:athymic nude/nude; Harlan). After 3–8 weeks, visible tumors arose
and therapy started when tumors size reached 50–100 mm3. Salubrinal
(1 mg/kg), oxaliplatin (1 mg/kg), a combination of both, or DMSO control was
injected intraperitoneally once a week for 4 weeks. Tumor growth was
measured once a week, and all mice were sacrificed when the tumor size
reached1cm3. For in vivo limitingdilution assay, spheroid cultureswere treated
with SubAB or SubA272B control for 24 hr and Wnt-GFP
high cells were sorted
directly intoMatrigel and injected subcutaneously into nudemice (Hsd:athymic
nude/nude; Harlan) as described previously (Vermeulen et al., 2010). Tumor
development was assessed weekly until 10 weeks after injection.
Statistical Analysis
Data are expressed as mean ± SEM. Unless otherwise indicated, statistical
significancewas determined by ANOVA (oneway or twoway) with a Bonferroni
post test. For statistical analysis of Kaplan-Meier, survival curves with log rank
(Mantel-Cox) test were performed followed by Bonferroni post test for multiple
comparisons. For limiting dilution assays, clonal frequency and statistical sig-
nificance were evaluated with the Extreme Limiting-dilution Analysis (ELDA)
‘‘limdil’’ function (http://bioinf.wehi.edu.au/software/elda/index.html; Hu and
Smyth, 2009). All significance was defined as *p < 0.05, **p < 0.01, and
***p < 0.001.
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